http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

Well, you never know....

Its all about keeping your nerve lol. The broker has a 13.3p target. This one does seem to move in the +8% to -8% range. Some more positive news and we will get there,

On Friday, Summit Corporation PLC (SUMM:LSE) closed at 5.25, 35.98% below its 52-week high of 8.20, set on Mar 15, 2012.


As of Mar 15, 2013, the consensus forecast amongst 3 polled investment analysts covering Summit Corporation plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 03, 2010. The previous consensus forecast advised investors to purchase equity in Summit Corporation plc.

hmm..might be a good time to buy more ...will think on it...there are afew others I'm thinking of going in on IAE is one of them..

Do you hold any other shares DC?

A lot at the moment, in most of of the stocks I have posted on. Some doing very well ie Wand, condor. A lot of them tend to drift back with lack of news one being edge resources, made a 100% + sold and back in again with the start of drilling. Been a great share that one. Had very good run the last few months. Just hope it lasts for all of us. Prefer being in the smaller company's
as the sp does move faster. There is more risk and if it goes right, more reward.

Summit outlines next steps in development of potentially breakthrough treatment
7:31 am by Ian LyallMaking the case: The company said it plans to present its utrophin modulator programme at what it described as a “major international conference” being held later this spring.

The drug discovery group Summit (LON:SUMM) has outlined its plans to further develop a potentially breakthrough treatment for muscle wasting disorder Duchenne Muscular Dystrophy.

Its lead drug candidate SMT C1100 is expected to enter clinical trials in patients in the second half of the year.

The study will be split into two. One part will concentrate on determining whether the drug is safe and well tolerated by children while assessing its C1100’s pharmacokinetics - in layman’s terms what the drug actually does to the body.

The treatment is designed stimulate production of a protein call utrophin, similar to dystrophin, which regulates muscle tone and function. It is hoped C1100 will restore and maintain healthy muscle function.

The second part of the study is a phase II trial that will include clinical markers of muscle health as well as levels of utrophin expression.

The biomarker programme has begun and includes the collaboration with Children’s National Medical Center of Washington DC, funded by the DMD organisation, The Foundation to Eradicate Duchenne.

The company said it plans to present its utrophin modulator programme at what it described as a “major international conference” being held later this spring.

Chief executive Glyn Edwards said: “Summit has a unique opportunity to develop a high-value franchise in utrophin modulation, an innovative therapeutic approach for DMD that targets all genetic forms of this devastating disease.

“These clinical trials will be the first to evaluate utrophin modulation in patients, and they aim to quickly establish clinical proof of concept for SMT C1100 through the use of novel biomarkers developed to measure aspects of muscle health.

“The biomarker work, to be conducted side by side with our clinical development programme, will strengthen our DMD franchise and will enhance the commercial value of this asset.”

First patient studies represent "significant acceleration" of plans, says Edwards
4:45 pm by Giles Gwinnett and Ian LyallThe treatment is designed to stimulate production of a protein called utrophin, similar to dystrophin, which regulates muscle tone and function. It is hoped C1100 will restore and maintain healthy muscle function

The first patient studies of Summit's (LON:SUMM) potentially breakthrough treatment for Duchenne Muscular Dystrophy (DMD) represents a "significant acceleration" in the development programme, says chief executive Glyn Edwards.

Lead drug candidate SMT C1100 is expected to enter clinical trials in patients in the second half of the year.

"I think there was a perception out in the market that we were not going to be getting into patients until next year but what we've announced here is that the first patient studies will be starting later this year, with more studies next year, obviously, but it's a significant acceleration of the programme from people's expectations," he explained to Proactive.

He said the firm had flagged up at the end of the last trial last year that it would take all of this year to get things ready for this next step but Edwards says hard work has brought this timeline forward.

As reported earlier, the study will be split into two.

One part will concentrate on determining whether the drug is safe and well tolerated by children while assessing its C1100’s pharmacokinetics - in layman’s terms what the drug actually does to the body.

The treatment is designed to stimulate production of a protein called utrophin, similar to dystrophin, which regulates muscle tone and function. It is hoped C1100 will restore and maintain healthy muscle function.

The second part of the study is a phase II trial that will include clinical markers of muscle health as well as levels of utrophin expression.

The biomarker programme has begun and includes the collaboration with Children’s National Medical Center of Washington DC, funded by the DMD organisation, The Foundation to Eradicate Duchenne.

The company also said earlier it plans to present its utrophin modulator programme at what it described as a “major international conference” being held later this spring.

Edwards told investors: “Summit has a unique opportunity to develop a high-value franchise in utrophin modulation, an innovative therapeutic approach for DMD that targets all genetic forms of this devastating disease.

“These clinical trials will be the first to evaluate utrophin modulation in patients, and they aim to quickly establish clinical proof of concept for SMT C1100 through the use of novel biomarkers developed to measure aspects of muscle health.

“The biomarker work, to be conducted side by side with our clinical development programme, will strengthen our DMD franchise and will enhance the commercial value of this asset.”

Shares dipped 0.92% to 5.375p.

hopefully we'll see more & stronger broker notes/recommendations soon

Summit schedules FY results

9 April 2013 | 14:59pm

StockMarketWire.com - Summit - a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infections - will announce its preliminary results for the year to the end of January on 11 April.

At 2:59pm: [LON:SUMM] share price was +0.01p at 4.38p

Sold my holding

Summit antibiotic reveals encouraging early potential
By Ian Lyall April 24 2013, 7:32am The Summit drug candidate is part of a new class of antibiotics that are high potency and selective for one particular infection – in this case the so-called super-bug C.diff.The Summit drug candidate is part of a new class of antibiotics that are high potency and selective for one particular infection – in this case the so-called super-bug C.diff.

Summit (LON:SUMM) has unveiled encouraging early results from clinical trials on the antibiotic it is developing for C.difficile.

The phase I study on 56 healthy patients revealed SMT 19969 is both safe and well tolerated in the doses that would be required to treat patients.

The Summit drug candidate is part of a new class of antibiotics that are high potency and selective for one particular infection – in this case the so-called super-bug C.diff.

Researchers assessed 19969’s potential to target infections by looking at the gut flora in the volunteers. They found that it was “highly sparing” of gut flora with only the clostridia bacterial family reduced to levels below the limit of detection.

"The positive safety and tolerability of SMT 19969 in this human phase I trial is a major success," said Summit chief executive Glyn Edwards.

"The results of the gut flora analysis are particularly encouraging because they indicate that SMT 19969 could target C. difficile without undermining the natural balance of gut flora.

“This reinforces our belief that SMT 19969 can become a breakthrough treatment for this life-threatening disease."

Professor Mark Wilcox, Consultant Head of Microbiology at the Leeds Teaching Hospitals NHS Trust, added: “It is very encouraging that in human volunteers SMT 19969 is highly sparing of gut flora.

“This offers promise as a much needed alternative treatment for this potentially serious disease."

Summit Appoints Dr David Roblin as Chief Medica...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF MEDICAL OFFICER

Oxford, UK, 12 June 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection ('CDI'), is pleased to announce the appointment of Dr David Roblin as the Company's Chief Medical Officer ('CMO'). During an extensive career in the pharmaceutical industry, Dr Roblin has successfully developed drugs through clinical trials and market launch across several therapy areas including infectious and metabolic diseases.

"As one of Europe's leading experts in translational medicine, I am delighted David has joined Summit as Chief Medical Officer to strengthen our clinical development team", commented Glyn Edwards, Chief Executive Officer of Summit. "David brings considerable expertise in all aspects of drug development having been instrumental in the successful development of a number of important medicines. As our DMD and CDI drug programmes go through patient clinical trials, David will make a major contribution to their successful development."

Summit's new Chief Medical Officer, Dr David Roblin, added, "SMT C1100 and SMT 19969 are promising new drugs, based on innovative science, that have the potential to address medical and patient need and, as a result, become breakthrough treatments for two devastating diseases. I look forward to working with the high quality team at Summit and supporting the development of these programmes as they progress through patient clinical trials."

About Dr David Roblin MBBS, BSc, FRCP, MFPM
Dr David Roblin is a qualified medical doctor who after practicing medicine entered the pharmaceutical and biotechnology industry. He has extensive experience from an 18-year career in the industry during which he has been involved in the successful development of a number of important medicines in a range of therapy areas including infectious and metabolic diseases.

David has held a number of senior leadership roles at Pfizer and Bayer where he was involved in research, development and commercialisation. At Pfizer, he was Head of Research, Site Director and CMO for Europe R&D and he and his units were responsible for the development of several important and successful medicines. At Bayer, he was Head of Therapy Area for Anti-infectives where he was involved in the successful development of a number of antibiotics, including Avelox(TM) and Cipro(TM).

Having held a number of Executive and Non-Executive Board positions, David also has experience in commercial and R&D strategy, fundraising and securing non-dilutive grants from a various UK, European and US government bodies. He will divide his time between Summit and Creabilis SA where he is also CMO. He is currently a Director of Destiny Pharma and Bio-Industry Advisor to the National Office of Research Infra-structure in the Department of Health.

David previously practiced medicine at St George's and St Bartholomew's Hospital, London, holds a degree in Biochemistry (University of London) and is a Fellow of the Royal College of Physicians and Member of the Faculty of Pharmaceutical Physicians.

- END -

At the recent AGM, the company said that a successful Phase 2 trial of SMT19969 could be worth £300 - £400m.

Therefore...

* Successful SMT19969 Phase II should add at least £300m of value by end of 2014.
* £300m = share price of 85p.
* So, 20 bagger in 18 months (On C. Diff alone!)
* PLUS - DMD SMTC1100 ($multi-billion market).
* PLUS - 'Lottery ticket' BMS/Seglin research.

Summit CEO says CMO appointment a "great catch" for the Co.
By Jeremy Naylor

http://www.proactiveinvestors.co.uk/companies/stocktube/2046/summit-ceo-says-cmo-appointment-a-great-catch-for-the-co--2046.html

N+1 Singer kept its ‘buy’ rating and 9p target price on Summit Corporation (LON:SUMM) today.

It comes as the drug developer said the successful completion of phase I clinical trials on SMT 19969, its antibiotic for C.difficile, triggered a £740,000 payment from the Wellcome Trust medical charity.

“The group’s development progression remains on track and we remain positive on its future prospects,” the broker said.


http://www.proactiveinvestors.co.uk/columns/broker-spotlight/13277/broker-round-up-ii-ariana-resources-new-world-oil-gas-kryso-resources-summit-corporation-13277.html

Sounds good..hopefully the sp will be a lot higher in 18months... still think this will tread water for the next year and then ..boom! (imho)... will top up at these levels in the meantime as funds become available

looks good.

Looks VERY good.

Just needs some patience!

As Hybridan recently said...

"Untenable Discount

We believe the huge valuation gulf between Summit and its peers is unsustainable; if financial markets don’t appreciate this then we would expect strategic investors to grab the opportunity sooner or later."

Placing to Raise GBP4.5M and Offer for Subscrip...

HUG


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Summit Corporation plc
('Summit' or 'the Company')

PROPOSED PLACING AND OFFER FOR SUBSCRIPTION TO QUALIFYING SHAREHOLDERS AND NOTICE OF GENERAL MEETING

Oxford, UK, 3 July 2013 - Summit (AIM: SUMM), a drug discovery and development company announces a share issue to raise GBP4.5 million (before expenses) through the issue of 90,750,000 new Ordinary Shares by way of a Placing at 5.0 pence per Ordinary Share to certain institutional investors and Directors. The Placing is being fully underwritten by Nomura Code Securities Limited on, and subject to, the terms of a placing agreement between the parties.

The issue price represents a premium of approximately 17.6 per cent. to the price of 4.25 pence per share, being the closing mid-market price of the Company's Ordinary Shares on 2 July 2013.

Glyn Edwards, Chief Executive Officer of Summit commented: "We are pleased to have received the support of existing shareholders and experienced healthcare investors in this placing that will maintain the development of our DMD programme while our novel C. difficile antibiotic continues to be supported by the Wellcome Trust."

Qualifying Shareholders will also be given an opportunity to participate in an Offer for Subscription of new Ordinary Shares at 5.0 pence per new Ordinary Share to raise up to GBP1.0 million in addition to the funds raised from the Placing.

A circular relating to the Placing and the Offer for Subscription will be posted to shareholders today. The circular contains a Notice of General Meeting to approve, inter alia, the issuance of the new Ordinary Shares pursuant to the Placing and the Offer for Subscription. The meeting will be held at the offices of Fasken Martineau LLP, 17 Hanover Square, London, W1S 1HU on 19 July 2013 at 10:00 a.m.

The circular will soon be available to view on the Company's website (www.summitplc.com) and copies will also be available from the registered office of Summit, 85b Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY.

- END -

Summit Corporation: N+1 Singer shifts target price from 9p to 8.80p keeping a buy recommendation